Skip to main content
Top
Published in: Rheumatology International 9/2017

01-09-2017 | Epidemiology of RMD

Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children

Authors: Sulaiman M. Al-Mayouf, Nora AlMutiari, Mohammed Muzaffer, Rawiah shehata, Adel Al-Wahadneh, Reem Abdwani, Safia Al-Abrawi, Mohammed Abu-shukair, Zeyad El-Habahbeh, Abdullah Alsonbul

Published in: Rheumatology International | Issue 9/2017

Login to get access

Abstract

This study describes the disease characteristics and outcome of Arab children with juvenile dermatomyositis (JDM) and compares the findings with other ethnicities. We retrospectively reviewed the hospital registries of the participating hospitals for children with JDM seen between 1990 and 2016 in three Arab countries. All patients fulfilled Bohan and Peter criteria for JDM, diagnosed before 14 years of age and were of Arab ethnicity. Clinical and laboratory features as well as the long-term outcomes including accrual disease damage were collected at the last follow-up visit. A total of 92 JDM patients (58 girls) were included. Mean age at the onset was 6 ± 3 years, with a mean follow-up duration of 5 ± 4.4 years. Forty-three patients (46.7%) had polycyclic disease course, 34 (36.9%) had a monocyclic course, while 15 (16.3%) had a continuous progressive course. Forty-five patients (48.9%) had arthritis, 14 (15.2%) patients had an upper airway and dysphagia, and 10 patients (10.9%) had lung involvement. Eight patients (8.7%) were admitted to the intensive care unit (ICU), 4 of them required mechanical ventilation. Methotrexate had been the most frequently used immunosuppressive drug (86%) and rituximab was used in eight patients. Additionally, 31 patients received IVIG. Most of the patients achieved a complete clinical response, but 16 ended up with permanent skin changes and 12 had a residual muscle weakness. Twenty-seven patients developed calcinosis. There were two deaths due to infection during the follow-up period. We report the largest phenotypic data on Arab children with JDM. Our patients have similar characteristics to previously described cohorts. Majority of the patients remained with inactive disease.
Literature
1.
go back to reference Mendez E, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A (2003) US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49:300–305CrossRefPubMed Mendez E, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A (2003) US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49:300–305CrossRefPubMed
2.
go back to reference Feldman B, Rider L, Reed A, Pachman LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of children. Lancet 28:2201–2212CrossRef Feldman B, Rider L, Reed A, Pachman LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of children. Lancet 28:2201–2212CrossRef
3.
go back to reference Rider L, Katz I, Jones O (2013) Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin N Am 39:877–904CrossRef Rider L, Katz I, Jones O (2013) Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin N Am 39:877–904CrossRef
4.
go back to reference Wedderburn L, Li C (2004) Paediatric idiopathic inflammatory muscle disease. Best Pract Res Clin Rheumatol 18:345–358CrossRefPubMed Wedderburn L, Li C (2004) Paediatric idiopathic inflammatory muscle disease. Best Pract Res Clin Rheumatol 18:345–358CrossRefPubMed
5.
go back to reference Gowdie P, Allen R, Kornberg A, Akikusa J (2013) Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis 16:561–567CrossRefPubMed Gowdie P, Allen R, Kornberg A, Akikusa J (2013) Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis 16:561–567CrossRefPubMed
6.
go back to reference Constantin T, Ponyi A, Orban I, Molnar K, Derfalvi B, Dicso F (2006) National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary—clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity 39:223–232CrossRefPubMed Constantin T, Ponyi A, Orban I, Molnar K, Derfalvi B, Dicso F (2006) National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary—clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity 39:223–232CrossRefPubMed
7.
go back to reference Shah M, Mamyrova G, Targoff I, Huber A, Malley J, Rice M et al (2013) The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92:25–41CrossRef Shah M, Mamyrova G, Targoff I, Huber A, Malley J, Rice M et al (2013) The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92:25–41CrossRef
8.
go back to reference Ernste F, Reed A (2014) Recent advances in juvenile idiopathic inflammatory myopathies. Curr Opin Rheumatol 26:671–678CrossRefPubMed Ernste F, Reed A (2014) Recent advances in juvenile idiopathic inflammatory myopathies. Curr Opin Rheumatol 26:671–678CrossRefPubMed
9.
go back to reference Singh S, Suri D, Aulakh R, Gupta A, Rawat A, Kumar R (2016) Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care in North India. Clin Rheumatol 33:1675–1679CrossRef Singh S, Suri D, Aulakh R, Gupta A, Rawat A, Kumar R (2016) Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care in North India. Clin Rheumatol 33:1675–1679CrossRef
10.
go back to reference Saini I, Kalaivani M, Kabra S (2016) Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int 36:961–965CrossRefPubMed Saini I, Kalaivani M, Kabra S (2016) Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int 36:961–965CrossRefPubMed
11.
go back to reference Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N et al (2011) European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 29:117–124PubMed Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N et al (2011) European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 29:117–124PubMed
12.
go back to reference Huber A, Lang B, LeBlanc C, Birdi N, Bolaria R, Mallseon P et al (2000) Medium-and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43:541–549CrossRefPubMed Huber A, Lang B, LeBlanc C, Birdi N, Bolaria R, Mallseon P et al (2000) Medium-and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43:541–549CrossRefPubMed
13.
go back to reference Kishi T, Miyamae T, Hara R, Nakajima S, Imagawa T, Mori M et al (2013) Clinical analysis of 50 children with dermatomyositis. Mod Rheumatol 23:311–317CrossRefPubMed Kishi T, Miyamae T, Hara R, Nakajima S, Imagawa T, Mori M et al (2013) Clinical analysis of 50 children with dermatomyositis. Mod Rheumatol 23:311–317CrossRefPubMed
14.
go back to reference Sun C, Lee J, Yang Y, Yu H, Wang L, Lin Y et al (2015) Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. Pediatr Neonatol 56:31–39CrossRefPubMed Sun C, Lee J, Yang Y, Yu H, Wang L, Lin Y et al (2015) Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. Pediatr Neonatol 56:31–39CrossRefPubMed
15.
go back to reference Shehata R, Al-Mayouf S, Al-Dalaan A, Al-Mazaid A, Al-Balaa S, Bahabri S (1999) Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol 17:115–118PubMed Shehata R, Al-Mayouf S, Al-Dalaan A, Al-Mazaid A, Al-Balaa S, Bahabri S (1999) Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol 17:115–118PubMed
16.
go back to reference Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C et al (2013) The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 72:686–693CrossRefPubMed Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C et al (2013) The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 72:686–693CrossRefPubMed
17.
go back to reference McCann L, Junggins A, Maillard S, Wedderburn L, Davidson J, Murray K et al (2006) The juvenile dermatomyositis national registry and repository (UK and Ireland)-clinical characteristics of children recruited with the first 5 yr. Rheumatology (Oxford) 45:1255–1260CrossRef McCann L, Junggins A, Maillard S, Wedderburn L, Davidson J, Murray K et al (2006) The juvenile dermatomyositis national registry and repository (UK and Ireland)-clinical characteristics of children recruited with the first 5 yr. Rheumatology (Oxford) 45:1255–1260CrossRef
18.
go back to reference Stringer E, Singh-Grewal D, Feldman B (2008) Predicting the course of juvenile dermatomyositis. Arthritis Rheum 58:3585–3592CrossRefPubMed Stringer E, Singh-Grewal D, Feldman B (2008) Predicting the course of juvenile dermatomyositis. Arthritis Rheum 58:3585–3592CrossRefPubMed
19.
go back to reference Patwardhan A, Rennebohm R, Dvorchik I, Spencer C (2012) Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center’s experience. Pediatr Rheumatol Online J 10(1):34. doi:10.1186/1546-0096-10-34 CrossRefPubMedPubMedCentral Patwardhan A, Rennebohm R, Dvorchik I, Spencer C (2012) Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center’s experience. Pediatr Rheumatol Online J 10(1):34. doi:10.​1186/​1546-0096-10-34 CrossRefPubMedPubMedCentral
20.
go back to reference Ponyi A, Constantin T, Balogh Z, Szalai Z, Borgulya G, Molnar K et al (2005) Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rehuamtol 23:50–56 Ponyi A, Constantin T, Balogh Z, Szalai Z, Borgulya G, Molnar K et al (2005) Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rehuamtol 23:50–56
21.
go back to reference Al-Mayouf SM, Al-Mazyed A, Bahabri S (2000) Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19:138–141CrossRefPubMed Al-Mayouf SM, Al-Mazyed A, Bahabri S (2000) Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19:138–141CrossRefPubMed
23.
go back to reference Al-Mayouf SM, Laxer R, Schneider R, Silverman E, Feldman B (2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27:2498–2503PubMed Al-Mayouf SM, Laxer R, Schneider R, Silverman E, Feldman B (2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27:2498–2503PubMed
24.
go back to reference Marco Puche A, Calvo Penades I, Lopez Montesinos B (2010) Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28:135–140PubMed Marco Puche A, Calvo Penades I, Lopez Montesinos B (2010) Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28:135–140PubMed
25.
go back to reference Sanner H, Gran J, Sjaastad I, Flato B (2009) Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years symptom onset. Rheumatology (Oxford) 48:154–157CrossRef Sanner H, Gran J, Sjaastad I, Flato B (2009) Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years symptom onset. Rheumatology (Oxford) 48:154–157CrossRef
Metadata
Title
Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children
Authors
Sulaiman M. Al-Mayouf
Nora AlMutiari
Mohammed Muzaffer
Rawiah shehata
Adel Al-Wahadneh
Reem Abdwani
Safia Al-Abrawi
Mohammed Abu-shukair
Zeyad El-Habahbeh
Abdullah Alsonbul
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 9/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3770-x

Other articles of this Issue 9/2017

Rheumatology International 9/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.